
Clinical Trials - May 1, 2016
BioInvent initiates Phase I/IIa study
BioInvent International has initiated a Phase I/IIa study that will evaluate the safety and tolerability, and explore the preliminary efficacy, of TB-403 for the treatment of relapsed or refractory medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. The study initiation follows the earlier announced partnership between BioInvent, its TB-403 project partner Oncurious, and […]

Biotech Business - March 16, 2016
Oncurious & BioInvent partner with US Research Consortium
Oncurious NV, an oncology company focused on the development of orphan drugs for the treatment of pediatric tumors, has signed a partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), a collaboration of 25 US academic medical centers, teaching hospitals and other entities, with the purpose of facilitating and conducting collaborative research activities and […]